NCT06699771View on ClinicalTrials.gov

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

August 31, 2027

Conditions
Lymphoma, T-Cell
Interventions
DRUG

GCC2005

CAR-NK Cell Therapy

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

Trial Locations (3)

03080

RECRUITING

Seoul National University Hosptial, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Artiva Biotherapeutics, Inc.

INDUSTRY

lead

GC Cell Corporation

INDUSTRY

NCT06699771 - Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | Biotech Hunter | Biotech Hunter